Full Paper
Coordinates of the calculated structures are given in Table S4 (see
the Supporting Information).
case of aryl substituted by electron donating groups. Ultimate-
ly, we anticipate that this radiolabeling approach will become
a highly useful tool for the radiolabeling of biomolecules with
heavy radiohalogens with applications in nuclear imaging and
targeted radiotherapy. Through the development of specifically
designed iodonium salts, such efforts are underway in our lab-
oratory.
Acknowledgements
This research was supported by the Intramural Research Pro-
gram of the NIH, National Cancer Institute, Center for Cancer
Research and Center for Information Technology and in part by
grants from the French National Agency for Research, called
“Investissements d’Avenir” IRON Labex (no. ANR-11-LABX-0018-
01) and ArronaxPlus Equipex (no. ANR-11-EQPX-0004). The
quantum chemical study utilized PC/linux clusters at the
center for Molecular Modeling of the National Institutes of
for his cyclotron operations and irradiation of bismuth targets
for the production of 211At. Professor Vanelle is thanked for the
input on radical mechanism investigations.
Experimental Section
Radiochemistry
[
125I]NaI was obtained commercially in 10ꢀ5 m NaOH solution with
a volumic acitivity of 50 mCimLꢀ1 (1.85 MBq/mL) and was diluted
12 times in deionized water before use. 211At was produced by
using the 209Bi(a,2n)211At reaction by bombarding a disposable in-
ternal bismuth target with a-particles from the Cyclotron Corpora-
tion CS-30 cyclotron in the National Institutes of Health Positron
Emission Tomography Department. 211At was recovered from the ir-
radiated target in acetonitrile by using a previously described dry-
distillation procedure.[44] Before use, the 211At solution was diluted
twice in a 10 mgmLꢀ1 aqueous solution of Na2SO3, resulting in
a 1:1 MeCN/water solution of sodium astatide. Iodonium salts were
obtained commercially or synthesized as described in the Support-
ing Information.
Keywords: astatine
·
halogenation
·
iodonium salts
·
nucleophilic substitution · radiopharmaceuticals
[1] E. A. Merritt, B. Olofsson, Angew. Chem. Int. Ed. 2009, 48, 9052–9070;
Angew. Chem. 2009, 121, 9214–9234.
[2] V. V. Zhdankin, P. J. Stang, Chem. Rev. 2008, 108, 5299–5358.
[3] F. M. Beringer, E. J. Geering, I. Kuntz, M. Mausner, J. Phys. Chem. 1956,
60, 141–150.
Reaction of iodonium salts with 125Iꢀ and 211Atꢀ
[4] F. M. Beringer, M. Mausner, J. Am. Chem. Soc. 1958, 80, 4535–4536.
[5] B. Hu, W. H. Miller, K. D. Neumann, E. J. Linstad, S. G. DiMagno, Chem.
Eur. J. 2015, 21, 6394–6398.
[6] M. Tredwell, V. Gouverneur, Angew. Chem. Int. Ed. 2012, 51, 11426–
11437; Angew. Chem. 2012, 124, 11590–11602.
[7] T. L. Ross, J. Ermert, C. Hocke, H. H. Coenen, J. Am. Chem. Soc. 2007,
129, 8018–8025.
[8] J.-H. Chun, S. Lu, Y.-S. Lee, V. W. Pike, J. Org. Chem. 2010, 75, 3332–
3338.
[9] N. Ichiishi, A. F. Brooks, J. J. Topczewski, M. E. Rodnick, M. S. Sanford,
P. J. H. Scott, Org. Lett. 2014, 16, 3224–3227.
[10] B. S. Moon, H. S. Kil, J. H. Park, J. S. Kim, J. Park, D. Y. Chi, B. C. Lee, S. E.
Kim, Org. Biomol. Chem. 2011, 9, 8346–8355.
To iodonium salt (950 nmol) in the selected solvent (190 mL) equili-
brated at the appropriate temperature of reaction was added
[
125I]NaI or [211At]NaAt solution (10 mL, typically 1.5 MBq), prepared
as described above. At desired times, aliquots were withdrawn and
deposited on a silica gel TLC plate and eluted with the appropriate
solvent, and/or diluted in a 1:1 water/MeCN mixture and analyzed
by reverse-phase HPLC using the appropriate elution system. Re-
tention indices and elution systems used for all compounds of this
study are given in the Supporting Information. Aromatic 125I and
211At species were identified by comparison of the retention index
of authentic samples of the non-radioactive iodinated compound.
[11] S. Telu, J.-H. Chun, F. G. Simꢀon, S. Lu, V. W. Pike, Org. Biomol. Chem.
2011, 9, 6629–6638.
[12] M.-R. Zhang, K. Kumata, M. Takei, T. Fukumura, K. Suzuki, Appl. Radiat.
Isot. 2008, 66, 1341–1345.
[13] S. Dimagno, B. Hu, Radioiodinated Compounds, 2015, WO2015147950
(A2).
[14] M. J. Adam, D. S. Wilbur, Chem. Soc. Rev. 2005, 34, 153–163.
[15] H. H. Coenen, S. M. Moerlein, G. Stçcklin, Radiochim. Acta 1983, 34, 47–
68.
Astatination via electrophilic destannylation
To a 2.5 mgmLꢀ1 solution of tributyl(4-tertbutylphenyl)-stannane in
99:1 MeCN/AcOH (20 mL) was added 2 mgmLꢀ1 N-chlorosuccini-
mide in MeCN (5 mL), followed by the 211At (5 MBq activity) in
MeCN (75 mL). The solution was heated for 30 min at 608C and
after cooling down to room temperature, the solution was diluted
with water (100 mL) and an aliquot was analyzed by HPLC, using
the same chromatographic system as described above.
[16] F. Guꢀrard, J.-F. Gestin, M. W. Brechbiel, Cancer Biother. Radiopharm.
2013, 28, 1–20.
[17] A. A. Cant, S. Champion, R. Bhalla, S. L. Pimlott, A. Sutherland, Angew.
Chem. Int. Ed. 2013, 52, 7829–7832; Angew. Chem. 2013, 125, 7983–
7986.
Quantum chemistry
The X-ray structure of bis(4-tert-butylphenyl)iodonium iodide was
used as a template to construct both the monomeric and heterodi-
meric structures of Ar2I+ complexed with iodide or astatide. Quan-
tum chemical calculations were carried out with the density func-
tional theory at the B3LYP level with small-core pseudopotentials[45]
for the I and At atoms with the cc-pVDZ basis set for their 25 va-
lence electrons, together with the all-electron cc-PVDZ basis set for
the rest of the atoms. All calculations were carried out in the reac-
tion field of MeCN with the polarizable continuum model, together
with the UAKS parameters set as implemented in Gaussian 09 soft-
ware.[46] For each TS, a single imaginary frequency was obtained.
[18] R. Yan, K. Sander, E. Galante, V. Rajkumar, A. Badar, M. Robson, E. El-
Emir, M. F. Lythgoe, R. B. Pedley, E. ꢂrstad, J. Am. Chem. Soc. 2013, 135,
703–709.
[19] D. S. Wilbur, Nat. Chem. 2013, 5, 246–246.
[20] S. Rothe, A. N. Andreyev, S. Antalic, A. Borschevsky, L. Capponi, T. E. Co-
colios, H. De Witte, E. Eliav, D. V. Fedorov, V. N. Fedosseev, D. A. Fink, S.
Fritzsche, L. Ghys, M. Huyse, N. Imai, U. Kaldor, Yuri Kudryavtsev, U.
Kçster, J. F. W. Lane, J. Lassen, Nat. Commun. 2013, 4, 1835.
[21] Y.-S. Kim, M. W. Brechbiel, Tumor Biol. 2012, 33, 573–590.
[22] G. Vaidyanathan, M. R. Zalutsky, Curr. Radiopharm. 2008, 1, 177–196.
[23] H. Rajerison, D. Faye, A. Roumesy, N. Louaisil, F. Boeda, A. Faivre-Chau-
vet, J.-F. Gestin, S. Legoupy, Org. Biomol. Chem. 2016, 14, 2121–2126.
Chem. Eur. J. 2016, 22, 1 – 9
7
ꢁ 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
&
&
These are not the final page numbers! ÞÞ